EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole
EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole
复制标题
DOI：
10.1111/j.1469-0691.2012.03890.x
复制
发表时间：
2012-07-01
影响因子：
14.2
通讯作者：
Hope, W. W.
中科院分区：
文献类型：
--
作者：
Arendrup, M. C.;Cuenca-Estrella, M.;Hope, W. W.
Clin Microbiol Infect 2012; 18：E248 E250摘要欧洲抗微生物药敏试验委员会抗真菌药敏试验小组委员会（EUCAST-AFST）已经确定了曲霉菌属的阿替霉素B、伊曲康唑和泊沙康唑的折点。本技术说明基于EUCAST阿替霉素B、伊曲康唑和泊沙康唑的基本原理文件（可在EUCAST网站上获得：）。阿替西霉素B和伊曲康唑折点基于流行病学临界值和临床经验。泊沙康唑折点也基于药代动力学和药效学数据。将定期或在出现新数据时审查断点。
Clin Microbiol Infect 2012; 18: E248E250 Abstract The European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has determined breakpoints for amphotericin B, itraconazole and posaconazole for Aspergillus species. This Technical Note is based on the EUCAST amphotericin B, itraconazole and posaconazole rationale documents (available on the EUCAST website: ). The amphotericin B and itraconazole breakpoints are based on epidemiological cut-off values and clinical experience. The posaconazole breakpoints are also based on pharmacokinetic and pharmacodynamic data. Breakpoints will be reviewed regularly or when new data emerge.